 Connection
David Simpson to Ritonavir
This is a "connection" page, showing publications David Simpson has written about Ritonavir.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.324 |
|
|
|
-
Bennett R, Chan H, Henderson R, Merriman E, Hanna M, Elinder-Camburn A, Simpson D. The addition of lopinavir-ritonavir to carfilzomib-based triplets can induce meaningful clinical response in carfilzomib-refractory myeloma patients: a single-center experience. Leuk Lymphoma. 2022 07; 63(7):1738-1741.
Score: 0.189
-
Croteau D, Letendre S, Best BM, Ellis RJ, Breidinger S, Clifford D, Collier A, Gelman B, Marra C, Mbeo G, McCutchan A, Morgello S, Simpson D, Way L, Vaida F, Ueland S, Capparelli E, Grant I. Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1. Antimicrob Agents Chemother. 2010 Dec; 54(12):5156-60.
Score: 0.086
-
Ma Q, Vaida F, Wong J, Sanders CA, Kao YT, Croteau D, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur JC, Morgello S, Simpson DM, Heaton RK, Grant I, Letendre SL. Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients. J Neurovirol. 2016 Apr; 22(2):170-8.
Score: 0.030
-
Best BM, Letendre SL, Brigid E, Clifford DB, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Simpson DM, Ellis R, Capparelli EV, Grant I. Low atazanavir concentrations in cerebrospinal fluid. AIDS. 2009 Jan 02; 23(1):83-7.
Score: 0.019
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|